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Further confirmation of broadly conserved, highly
immunogenic cross-clade HIV CTL epitopes for
inclusion in the GAIA HIV vaccine
AS De Groot1*, L Moise1, O Koita2, K Sangare2, L Levitz1, J Rozenhal3, Z Koty4, K Tounkara4, M Ardito1, CM Boyle1,
M Rochas4, W Martin1
From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012
Background
One of the biggest challenges for HIV vaccine design is
identifying conserved HLA Class I- and Class II-
restricted epitopes that would impart substantial fitness
cost to the virus, thereby controlling or preventing
infection. Here, we set out to develop an epitope-driven,
DNA-prime/pseudoprotein-boost HIV vaccine (GAIA
vaccine) composed of such epitopes.
Methods
Analysis was performed in 2003 on 10,803 HIV-1
sequences, and again in 2009, on an expanded set of
43,822 sequences. These were searched for conserved 9-
10-mer segments with the EpiMatrix suite of immunoin-
formatic algorithms. From the most highly conserved
(>5% isolates) or top 1,000 scoring 9-mers, HLA Class I
binding sequences and Class II immunogenic consensus
sequences (ICS) were identified for vaccine design. Vali-
dation was performed in Thailand, the USA, and Mali
via in vitro binding and IFN-g ELISpot assays, using
HIV-infected donor peripheral blood. HLA transgenic
mice were immunized in DNA-prime/peptide-boost vac-
cine studies including these epitopes.
Results
`Epitopes selected as described are more broadly con-
served than those selected for other epitope-based vac-
cines (>70%, compared to Epimmune’s 40%). Antigenicity
of 98% of ICS epitopes and Class I epitopes (87% A2,
29% A3, 67% B7, 20% A24) was confirmed in HIV-
infected subjects. Fifteen ICS peptides and 12 A2 peptides
were confirmed in both Mali and the USA. Sixteen A3
peptides were confirmed weighting sequences for conser-
vation and immunogenicity (as determined by EpiMatrix
score), in vitro binding, and positive ELISpot responses.
Epitope immunogenicity was validated in HLA transgenic
mouse immunization studies.
Conclusion
The GAIA vaccine approach is an effective means of
triaging HIV epitope sequences to identify the most
immunogenic and conserved epitope candidates across
HLA allotypes. HLA transgenic mouse studies showed
prototype DNA vaccines including these epitopes to be
immunogenic, suggesting the epitope-rich GAIA vaccine
would induce greater immunogenicity than other DNA/
viral vector prime-boost vaccines in humans.
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